Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253995 | 0.93 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1RNASEL | |
| SCHEMBL12397144 | 0.93 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10171408 | 0.89 | CYP3A4 (0.46) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10149599 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10149619 | 0.88 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL881392 | 0.87 | CYP3A4 (0.45) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10171411 | 0.87 | CYP3A4 (0.46) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10171410 | 0.86 | CYP3A4 (0.38) | CYP3A4CYP2C9 | |
| SCHEMBL13648768 | 0.86 | CYP3A4 (0.34) | CYP3A4CYP2C9BTN3A1RNASEL | |
| SCHEMBL10148674 | 0.85 | CYP3A4 (0.46) | CYP3A4CYP2C9BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |